Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)

Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)

Abstract Background Ritonavir-boosted nirmatrelvir (N/r) is an antiviral which targets the main viral protease, administered to prevent the progression of SARS-CoV-2 infection in patients at high risk for severe COVID-19. We present a real-life case-control study evaluating the efficacy of N/r thera...

Full description

Bibliographic Details
Main Authors: Ivan Gentile, Agnese Giaccone, Maria Michela Scirocco, Francesco Di Brizzi, Federica Cuccurullo, Maria Silvitelli, Luigi Ametrano, Francesco Antimo Alfè, Daria Pietroluongo, Irene Irace, Mariarosaria Chiariello, Noemi De Felice, Simone Severino, Giulio Viceconte, Nicola Schiano Moriello, Alberto Enrico Maraolo, Antonio Riccardo Buonomo, Riccardo Scotto, Federico II COVID team
Format: Article
Language:English
Published: BMC 2024-12-01
Series:BMC Infectious Diseases
Subjects:
SARS-CoV-2
COVID-19
Nirmatrelvir/ritonavir
Mortality
Early treatment
Online Access:https://doi.org/10.1186/s12879-024-10303-5

Internet

https://doi.org/10.1186/s12879-024-10303-5

Similar Items